好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Features and Neuroimaging of Anomic Progressive Aphasia
Aging, Dementia, and Behavioral Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
7-005

To characterize the neuroimaging, neuropsychologic features, and longitudinal outcomes of an anomic subtype of Primary Progressive Aphasia (PPA).

Many patients who have progressive aphasia do not meet criteria for the established PPA subtypes (Logopenic (LPA), Semantic (SD), or Agrammatic). One such subset presents with prominent anomia with spared repetition, grammar, motor speech, and semantic knowledge. We propose the term Anomic Progressive Aphasia (APA) to describe these cases and hypothesize that they represent mild cases of fluent aphasia that will ultimately progress to meet criteria for LPA, SD, or mixed SD-LPA.

Retrospective analysis identified 30 patients with possible APA recruited by the Neurodegenerative Research Group at Mayo Clinic between 2011-2021. Chart review and neuropsychological/language testing were used to exclude those with impaired repetition, semantic knowledge, grammar, or motor speech. We excluded those with moderate aphasia (WAB-AQ< 85) or significant cognitive impairment.

Nine patients were included (6 females, 3 males), with average education 16.5 years, average age at onset 66, and mean WAB-AQ 89.9 at presentation. Three of eight (38%) were amyloid-positive on PiB-PET, one of whom was also tau-positive on AV-1451-PET; two developed LPA and one had mixed SD-LPA. Two patients were tau-positive only, although on visual inspection likely due to off-target binding commonly associated with TDP-43 Type C pathology; both progressed to SD. Two with left anteromedial temporal hypometabolism on FDG-PET progressed to SD. Three with posterolateral temporal hypometabolism (two left, one right) progressed to LPA, two of whom also had parietal and frontal hypometabolism. One with left anteromedial temporal and frontal hypometabolism developed mixed SD-LPA. Three with parietal or frontal hypometabolism developed features of LPA (one mixed).

APA lies on the spectrum of aphasic disorders that do not clearly fit into established PPA subtypes. Molecular PET and FDG PET may help to predict the clinical course of APA.

Authors/Disclosures
Christine Cliatt Brown, MD (University of Utah)
PRESENTER
The institution of Dr. Cliatt Brown has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Open evidence . The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member with IMPACT AD .
Joseph Duffy The institution of Joseph Duffy has received research support from NIH. Joseph Duffy has received publishing royalties from a publication relating to health care.
Rene Utianski Rene Utianski has nothing to disclose.
Heather Clark The institution of Heather Clark has received research support from NIH. Heather Clark has received publishing royalties from a publication relating to health care.
Mary M. Machulda, PhD (Mayo Clinic) The institution of Dr. Machulda has received research support from NIH.
Wentao Li, MD (The Permanente Medical Group) Dr. Li has nothing to disclose.
Jennifer Whitwell, PhD (Mayo Clinic) The institution of Dr. Whitwell has received research support from NIH.
Keith A. Josephs, Jr., MD, FAAN (Mayo Clinic) Dr. Josephs has nothing to disclose.
Hugo Botha, MD (Mayo School of Graduate Medical 好色先生, Rochester) Dr. Botha has received research support from NIH. An immediate family member of Dr. Botha has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH.